SCHEMBL466063

SCHEMBL466063

CCCCC(C)CCCCCCC(=O)O

nearest known ligand 0.66

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FFAR4 Q5NUL3 2/20 0.66
FFAR1 O14842 2/20 0.66
GPR84 Q9NQS5 7/20 0.64
PPARG P37231 7/20 0.64
PPARD Q03181 7/20 0.64
PPARA Q07869 7/20 0.64
HDAC11 Q96DB2 5/20 0.64
TSHR P16473 4/20 0.64
PTPN1 P18031 3/20 0.64
ALDH1A1 P00352 3/20 0.64
TLR2 O60603 2/20 0.64
TDP1 Q9NUW8 2/20 0.64
FABP4 P15090 2/20 0.64
KMT2A Q03164 2/20 0.64
SLC22A6 Q4U2R8 1/20 0.64
SLC22A8 Q8TCC7 1/20 0.64
MEN1 O00255 1/20 0.64
ESR1 P03372 1/20 0.64
ALOX15 P16050 1/20 0.64
PDE4A P27815 1/20 0.64

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29070650 1.00 FFAR4 (0.66) FFAR4FFAR1GPR84PPARGPPARD
SCHEMBL26624736 1.00 FFAR4 (0.66) FFAR4FFAR1GPR84PPARGPPARD
SCHEMBL2812636 1.00 FFAR4 (0.66) FFAR4FFAR1GPR84PPARGPPARD
SCHEMBL541641 1.00 FFAR4 (0.66) FFAR4FFAR1GPR84PPARGPPARD
SCHEMBL253486 1.00 FFAR4 (0.66) FFAR4FFAR1GPR84PPARGPPARD
SCHEMBL16212818 1.00 FFAR4 (0.66) FFAR4FFAR1GPR84PPARGPPARD
SCHEMBL15491632 1.00 FFAR4 (0.66) FFAR4FFAR1GPR84PPARGPPARD
SCHEMBL12970879 1.00 FFAR4 (0.66) FFAR4FFAR1GPR84PPARGPPARD
SCHEMBL2182556 1.00 FFAR4 (0.66) FFAR4FFAR1GPR84PPARGPPARD
Octanoic Acid SCHEMBL26624670 0.98 FFAR4 (0.69) FFAR4FFAR1GPR84PPARGPPARD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 67 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-120053661-A Hydrophilic fatty acid complex for preventing, preventing or treating microbial infection, preparation and application thereof 太阳雨林(北京)生物医药有限公司 2025-05-30 CN disclosed
CN-120053660-A Hydrophilic complex for preventing, preventing or treating microbial infection, preparation and application thereof 太阳雨林(北京)生物医药有限公司 2025-05-30 CN disclosed
CN-119855607-A Carbon chain substance for regulating transmembrane transport and fluidity of cell membrane, preparation and application 太阳雨林(北京)生物医药有限公司 2025-04-18 CN disclosed
EP-4520348-A1 CARBON CHAIN SUBSTANCE FOR REGULATING TRANSMEMBRANE TRANSPORT AND FLUIDITY OF CELL MEMBRANES, AND PREPARATION AND USE THEREOF Sunforest (Beijing) Biopharma Ltd (CN) 2025-03-12 EP disclosed
WO-2023213310-A9 CARBON CHAIN SUBSTANCE FOR REGULATING TRANSMEMBRANE TRANSPORT AND FLUIDITY OF CELL MEMBRANES, AND PREPARATION AND USE THEREOF 太阳雨林(北京)生物医药有限公司 2025-02-20 WO disclosed
WO-2023213310-A1 CARBON CHAIN SUBSTANCE FOR REGULATING TRANSMEMBRANE TRANSPORT AND FLUIDITY OF CELL MEMBRANES, AND PREPARATION AND USE THEREOF 太阳雨林(北京)生物医药有限公司 2023-11-09 WO disclosed
US-11672758-B2 Endoxifen methods and compositions for inhibition of protein kinase C JINA PHARMACEUTICALS, INC. (US) 2023-06-13 US disclosed
CN-115607677-A Compound for preventing, preventing or treating microbial infection and preparation and application thereof 太阳雨林(北京)生物医药有限公司 2023-01-17 CN disclosed
CN-114569726-B Compound for preventing, preventing or treating microbial infection and preparation method and application thereof 太阳雨林(北京)生物医药有限公司 2022-10-28 CN disclosed
EP-2992031-B1 ALIPHATIC POLYCARBONATE COMPOSITIONS AND METHODS NOVOMER INC (US) 2022-10-05 EP disclosed
US-20050277611-A1 Cationic cardiolipin analoges and its use thereof NEOPHARM, INC. (US) 2005-12-15 US disclosed
US-20050266068-A1 Cardiolipin molecules and methods of synthesis NEOPHARM, INC. (US) 2005-12-01 US disclosed
EP-1558562-A1 CATIONIC CARDIOLIPIN ANALOGS AND USE THEREOF Neopharm, Inc. (US) 2005-08-03 EP disclosed
EP-1556392-A1 CARDIOLIPIN MOLECULES AND METHOD OF SYNTHESIS Neopharm, Inc. (US) 2005-07-27 EP disclosed
WO-2004039817-A9 CARDIOLIPIN MOLECULES AND METHOD OF SYNTHESIS NEOPHARM INC (US) 2004-07-22 WO disclosed
WO-2004039817-A1 CARDIOLIPIN MOLECULES AND METHOD OF SYNTHESIS NEOPHARM, INC. (US) 2004-05-13 WO disclosed
WO-2004035523-A1 CATIONIC CARDIOLIPIN ANALOGS AND USE THEREOF NEOPHARM, INC. (US) 2004-04-29 WO disclosed
CN-1013120-B IMPROVED PROCESS FOR PRODUCING A-21978C DERIVATIVE LILLY CO ELI (US) 1991-07-10 CN disclosed
CN-1051200-A The method for preparing the antimycin A-21978C mixture or the factor LILLY CO ELI (US) 1991-05-08 CN disclosed
CN-85107552-A A-21978C derivative production method is improved 1987-05-20 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050277611-A1 Cationic cardiolipin analoges and its use thereof LCLAT1, CETP, LIPA FFAR4 1413/4885FFAR1 1928/4885GPR84 1499/4885
US-20050266068-A1 Cardiolipin molecules and methods of synthesis PHOSPHO1, MGLL, LIPA FFAR4 272/4885FFAR1 271/4885GPR84 1999/4885
US-11672758-B2 Endoxifen methods and compositions for inhibition of protein kinase C EEF2K, LITAF, RAPGEF3 FFAR4 1959/4885FFAR1 1180/4885GPR84 2656/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.